BIOLASE, Inc. (BIOL)

Market Cap	5.26M
Revenue (ttm)	48.83M
Net Income (ttm)	-38.26M
Shares Out	33.40M
EPS (ttm)	-20.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,626,293
Open	0.185
Previous Close	0.159
Day's Range	0.151 - 0.185
52-Week Range	0.130 - 17.000
Beta	0.72
Analysts	Strong Buy
Price Target	14.80 (+9,208.18%)
Earnings Date	May 13, 2024

About BIOL

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; di...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 13, 1992
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOL

Financial Performance

In 2023, BIOLASE's revenue was $49.16 million, an increase of 1.45% compared to the previous year's $48.46 million. Losses were -$37.62 million, 30.4% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BIOL stock is "Strong Buy." The 12-month stock price forecast is $14.8, which is an increase of 9,208.18% from the latest price.

Price Target

$14.8

(9,208.18% upside)

Analyst Consensus: Strong Buy